Table 1.

Anti-angiogenic Therapies

Study Drug	Target	Prior Lines of Therapy	Patients	ORR	mTTP/PFS (months)	mOS (months)
Dalantercept [98]	BMP9/10	1–2	28	0%	2.1	14.5
Trebananib [99]	Tie2 Receptor	1–2	32	3.1%	2	6.6
Cediranib [96]	VEGF/c-kit	1–2	48	12.5%	3.7	12.5
Sunitinib [91]	VEGF/KIT/PDGFR	≤ 1	33	18.2%	3.0	19.4
Nintedanib [92]	VEGF/FGFR/PDGFR	1–2	32	9.4%	3.1	10.1
Lenvatinib [97]	VEGFR/FGFR/RET/KIT/PDGFRβ	1–2	133	14.3%	5.6	10.6
Aflibercept [95]	VEGFR	1–2	44	7%	2.9	14.6
Bevacizumab [87]	VEGFR	1–2	52	13.5%	4.2	10.6
Sorafenib [100]	VEGF/Raf/Ras	≤ 1	39	5%	3.2	11.4
Thalidomide [101]	VEGFR/bFGF	1–2	21	12.5%	1.7	6.3

ORR objective response rate, mTTP median time to progression, PFS progression-free survival, mOS median overall survival